Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
BIOMARKER:
EGFR overexpression
i
Other names:
EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Associations
(34)
News
Trials
B | Sensitive
C2 | Sensitive
C3 | Sensitive
C4 | Sensitive
D | Sensitive
B | Resistant
C2 | Resistant
C3 | Resistant
C4 | Resistant
D | Resistant
Show legend
Include preclinical:
Drug categories
EGFR
Tyrosine Kinase Inhibitors
Immunotherapy
Chemotherapy
DNA
FGF
BCL Inhibitors
Serine-Threonine Kinase Inhibitors
CD Protein Inhibitors
Immune Checkpoint Inhibitors
Hormone Therapy
Cyclin Dependent Kinase Inhibitors
Cancel
Non Small Cell Lung Cancer
Esophageal Squamous Cell Carcinoma
Gastric Cancer
Glioblastoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Lung Adenocarcinoma
Hepatocellular Cancer
Thyroid Gland Papillary Carcinoma
Mesothelioma
Estrogen Receptor Positive Breast Cancer
Solid Tumor
Triple Negative Breast Cancer
Breast Cancer
Pancreatic Cancer
Osteosarcoma
Lung Cancer
erlotinib
B
EGFR overexpression
|
Esophageal Squamous Cell Carcinoma
|
erlotinib
gefitinib
B
EGFR overexpression
|
Non Small Cell Lung Cancer
|
gefitinib
cetuximab
D
EGFR overexpression
|
Non Small Cell Lung Cancer
|
cetuximab
D
EGFR overexpression
|
Gastric Cancer
|
cetuximab
C2
EGFR overexpression
|
Squamous Cell Carcinoma of Head and Neck
|
cetuximab
C3
EGFR overexpression
|
Colorectal Cancer
|
cetuximab
gefitinib + lenvatinib
C3
EGFR overexpression
|
Hepatocellular Cancer
|
gefitinib + lenvatinib
larotrectinib
C4
EGFR overexpression
|
Thyroid Gland Papillary Carcinoma
|
larotrectinib
ABBV-321
C2
EGFR overexpression
|
Glioblastoma
|
ABBV-321
D
EGFR overexpression
|
Mesothelioma
|
ABBV-321
necitumumab
C2
EGFR overexpression
|
Non Small Cell Lung Cancer
|
necitumumab
Z650
C2
EGFR overexpression
|
Esophageal Squamous Cell Carcinoma
|
Z650
ASLAN001
C3
EGFR overexpression
|
Gastric Cancer
|
ASLAN001
GC-1118A
C3
EGFR overexpression
|
Gastric Cancer
|
GC-1118A
gemcitabine
D
EGFR overexpression
|
Osteosarcoma
|
gemcitabine
ABT 263 + ABBV-321
D
EGFR overexpression
|
Triple Negative Breast Cancer
|
ABT 263 + ABBV-321
ABT 263 + ABT-414
D
EGFR overexpression
|
Triple Negative Breast Cancer
|
ABT 263 + ABT-414
ONC201
D
EGFR overexpression
|
Glioblastoma
|
ONC201
cetuximab + avelumab
D
EGFR overexpression
|
Lung Cancer
|
cetuximab + avelumab
HTI-1511
D
EGFR overexpression
|
Non Small Cell Lung Cancer
|
HTI-1511
D
EGFR overexpression
|
Squamous Cell Carcinoma of Head and Neck
|
HTI-1511
D
EGFR overexpression
|
Pancreatic Cancer
|
HTI-1511
vandetanib
D
EGFR overexpression
|
Breast Cancer
|
vandetanib
nimotuzumab
D
EGFR overexpression
|
Esophageal Squamous Cell Carcinoma
|
nimotuzumab
afatinib + enzalutamide capsule
D
EGFR overexpression
|
Glioblastoma
|
afatinib + enzalutamide capsule
palbociclib
D
EGFR overexpression
|
Estrogen Receptor Positive Breast Cancer
|
palbociclib
BB-1705
D
EGFR overexpression
|
Solid Tumor
|
BB-1705
LR004-VC-MMAE
D
EGFR overexpression
|
Non Small Cell Lung Cancer
|
LR004-VC-MMAE
D
EGFR overexpression
|
Esophageal Squamous Cell Carcinoma
|
LR004-VC-MMAE
D
EGFR overexpression
|
Triple Negative Breast Cancer
|
LR004-VC-MMAE
D
EGFR overexpression
|
Breast Cancer
|
LR004-VC-MMAE
Immunotherapy
C3
EGFR overexpression
|
Non Small Cell Lung Cancer
|
Immunotherapy
EGFR inhibitor
C3
EGFR overexpression
|
Colorectal Cancer
|
EGFR inhibitor
Tyrosine kinase inhibitor
C3
EGFR overexpression
|
Lung Adenocarcinoma
|
Tyrosine kinase inhibitor
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
